OBJECTIVE: To determine the cost utility of medical co-prescription of heroin compared with methadone maintenance treatment for chronic, treatment resistant heroin addicts. DESIGN: Cost utility analysis of two pooled open label randomised controlled trials. SETTING: Methadone maintenance programmes in six cities in the Netherlands. PARTICIPANTS: 430 heroin addicts. INTERVENTIONS: Inhalable or injectable heroin prescribed over 12 months. Methadone (maximum 150 mg a day) plus heroin (maximum 1000 mg a day) compared with methadone alone (maximum 150 mg a day). Psychosocial treatment was offered throughout. MAIN OUTCOME MEASURES: One year costs estimated from a societal perspective. Quality adjusted life years (QALYs) based on responses to the EuroQol EQ-5D at baseline and during the treatment period. RESULTS: Co-prescription of heroin was associated with 0.058 more QALYs per patient per year (95% confidence interval 0.016 to 0.099) and a mean saving of 12,793 euros (8793 pounds sterling, 16,122 dollars) (1083 to 25,229 euros) per patient per year. The higher programme costs (16 222 euros; lower 95% confidence limit 15,084 euros) were compensated for by lower costs of law enforcement (- 4129 euros; upper 95% confidence limit - 486 euros) and damage to victims of crime (- 25,374 euros; upper 95% confidence limit - 16,625 euros). The results were robust for the use of national EQ-5D tariffs and for the exclusion of the initial implementation costs of heroin treatment. Completion of treatment is essential; having participated in any abstinence treatment in the past is not. CONCLUSIONS: Co-prescription of heroin is cost effective compared with treatment with methadone alone for chronic, treatment resistant heroin addicts.
OBJECTIVE: To determine the cost utility of medical co-prescription of heroin compared with methadone maintenance treatment for chronic, treatment resistant heroin addicts. DESIGN: Cost utility analysis of two pooled open label randomised controlled trials. SETTING:Methadone maintenance programmes in six cities in the Netherlands. PARTICIPANTS: 430 heroin addicts. INTERVENTIONS: Inhalable or injectable heroin prescribed over 12 months. Methadone (maximum 150 mg a day) plus heroin (maximum 1000 mg a day) compared with methadone alone (maximum 150 mg a day). Psychosocial treatment was offered throughout. MAIN OUTCOME MEASURES: One year costs estimated from a societal perspective. Quality adjusted life years (QALYs) based on responses to the EuroQol EQ-5D at baseline and during the treatment period. RESULTS: Co-prescription of heroin was associated with 0.058 more QALYs per patient per year (95% confidence interval 0.016 to 0.099) and a mean saving of 12,793 euros (8793 pounds sterling, 16,122 dollars) (1083 to 25,229 euros) per patient per year. The higher programme costs (16 222 euros; lower 95% confidence limit 15,084 euros) were compensated for by lower costs of law enforcement (- 4129 euros; upper 95% confidence limit - 486 euros) and damage to victims of crime (- 25,374 euros; upper 95% confidence limit - 16,625 euros). The results were robust for the use of national EQ-5D tariffs and for the exclusion of the initial implementation costs of heroin treatment. Completion of treatment is essential; having participated in any abstinence treatment in the past is not. CONCLUSIONS: Co-prescription of heroin is cost effective compared with treatment with methadone alone for chronic, treatment resistant heroin addicts.
Authors: Jan B Oostenbrink; Tineke Buijs-Van der Woude; Michel van Agthoven; Marc A Koopmanschap; Frans F H Rutten Journal: Pharmacoeconomics Date: 2003 Impact factor: 4.981
Authors: Carmen L Masson; Paul G Barnett; Karen L Sees; Kevin L Delucchi; Amy Rosen; Wynnie Wong; Sharon M Hall Journal: Addiction Date: 2004-06 Impact factor: 6.526
Authors: Christopher M Doran; Marian Shanahan; Richard P Mattick; Robert Ali; Jason White; James Bell Journal: Drug Alcohol Depend Date: 2003-09-10 Impact factor: 4.492
Authors: Benedikt Fischer; Eugenia Oviedo-Joekes; Peter Blanken; Christian Haasen; Jürgen Rehm; Martin T Schechter; John Strang; Wim van den Brink Journal: J Urban Health Date: 2007-07 Impact factor: 3.671
Authors: Dennis McCarty; Nancy A Perrin; Carla A Green; Michael R Polen; Michael C Leo; Frances Lynch Journal: Drug Alcohol Depend Date: 2010-10-01 Impact factor: 4.492
Authors: Emilio Perea-Milla; Luis Carlos Silva Ayçaguer; Joan Carles March Cerdà; Francisco González Saiz; Francisco Rivas-Ruiz; Alina Danet; Manuel Romero Vallecillo; Eugenia Oviedo-Joekes Journal: Trials Date: 2009-08-14 Impact factor: 2.279